Cargando…

Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease

Background: Cytomegalovirus (CMV) infection has been associated with venous thromboembolism (VTE) and acute coronary syndromes (ACS). Methods: A retrospective study was conducted within the OSF HealthCare System in Peoria, IL. The objectives were to determine the incidence of acute VTE and ACS withi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelkar, Amar H, Loc, Brian L, Tarantino, Michael D, Rajasekhar, Anita, Wang, Huaping, Kelkar, Mona, Farrell, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813978/
https://www.ncbi.nlm.nih.gov/pubmed/33489573
http://dx.doi.org/10.7759/cureus.12161
_version_ 1783637960956051456
author Kelkar, Amar H
Loc, Brian L
Tarantino, Michael D
Rajasekhar, Anita
Wang, Huaping
Kelkar, Mona
Farrell, John
author_facet Kelkar, Amar H
Loc, Brian L
Tarantino, Michael D
Rajasekhar, Anita
Wang, Huaping
Kelkar, Mona
Farrell, John
author_sort Kelkar, Amar H
collection PubMed
description Background: Cytomegalovirus (CMV) infection has been associated with venous thromboembolism (VTE) and acute coronary syndromes (ACS). Methods: A retrospective study was conducted within the OSF HealthCare System in Peoria, IL. The objectives were to determine the incidence of acute VTE and ACS within one year of CMV testing. The “study group” included patients with positive CMV immunoglobulin M (IgM) or positive CMV polymerase chain reaction (PCR). The “seropositive control” group included patients with positive CMV immunoglobulin G (IgG) and negative IgM. The “seronegative control” group included patients with negative CMV IgG and IgM, or negative PCR. Results: Within one year of CMV infection, 38 of 379 patients (10.0%) developed VTE in the study group compared to 41 of 1334 patients (3.1%) in the seropositive control and 37 of 1249 (3.0%) in the seronegative control. Adjusting for age and gender, both control groups were less likely to have VTE than the study group within one year (seropositive control: odds ratio (OR) = 0.3, 95% confidence interval (CI) 0.2-0.5, p < 0.0001; seronegative control: OR = 0.4, 95% CI 0.2-0.6, p < 0.0001). ACS was more likely to occur in the study group, with the incidence of 7.7% compared to 4.7% (p < 0.0001) in the seropositive control and 1.9% (p <0.0001) in the seronegative control. Adjusting for age and gender, the seronegative control was less likely to develop ACS than the study group within one year (OR = 0.4, 95% CI 0.2-0.7, p = 0.003). Conclusions: This retrospective study demonstrates that CMV infection may be a significant risk factor for VTE and ACS.
format Online
Article
Text
id pubmed-7813978
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-78139782021-01-22 Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease Kelkar, Amar H Loc, Brian L Tarantino, Michael D Rajasekhar, Anita Wang, Huaping Kelkar, Mona Farrell, John Cureus Cardiology Background: Cytomegalovirus (CMV) infection has been associated with venous thromboembolism (VTE) and acute coronary syndromes (ACS). Methods: A retrospective study was conducted within the OSF HealthCare System in Peoria, IL. The objectives were to determine the incidence of acute VTE and ACS within one year of CMV testing. The “study group” included patients with positive CMV immunoglobulin M (IgM) or positive CMV polymerase chain reaction (PCR). The “seropositive control” group included patients with positive CMV immunoglobulin G (IgG) and negative IgM. The “seronegative control” group included patients with negative CMV IgG and IgM, or negative PCR. Results: Within one year of CMV infection, 38 of 379 patients (10.0%) developed VTE in the study group compared to 41 of 1334 patients (3.1%) in the seropositive control and 37 of 1249 (3.0%) in the seronegative control. Adjusting for age and gender, both control groups were less likely to have VTE than the study group within one year (seropositive control: odds ratio (OR) = 0.3, 95% confidence interval (CI) 0.2-0.5, p < 0.0001; seronegative control: OR = 0.4, 95% CI 0.2-0.6, p < 0.0001). ACS was more likely to occur in the study group, with the incidence of 7.7% compared to 4.7% (p < 0.0001) in the seropositive control and 1.9% (p <0.0001) in the seronegative control. Adjusting for age and gender, the seronegative control was less likely to develop ACS than the study group within one year (OR = 0.4, 95% CI 0.2-0.7, p = 0.003). Conclusions: This retrospective study demonstrates that CMV infection may be a significant risk factor for VTE and ACS. Cureus 2020-12-18 /pmc/articles/PMC7813978/ /pubmed/33489573 http://dx.doi.org/10.7759/cureus.12161 Text en Copyright © 2020, Kelkar et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Kelkar, Amar H
Loc, Brian L
Tarantino, Michael D
Rajasekhar, Anita
Wang, Huaping
Kelkar, Mona
Farrell, John
Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease
title Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease
title_full Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease
title_fullStr Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease
title_full_unstemmed Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease
title_short Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease
title_sort cytomegalovirus-associated venous and arterial thrombotic disease
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813978/
https://www.ncbi.nlm.nih.gov/pubmed/33489573
http://dx.doi.org/10.7759/cureus.12161
work_keys_str_mv AT kelkaramarh cytomegalovirusassociatedvenousandarterialthromboticdisease
AT locbrianl cytomegalovirusassociatedvenousandarterialthromboticdisease
AT tarantinomichaeld cytomegalovirusassociatedvenousandarterialthromboticdisease
AT rajasekharanita cytomegalovirusassociatedvenousandarterialthromboticdisease
AT wanghuaping cytomegalovirusassociatedvenousandarterialthromboticdisease
AT kelkarmona cytomegalovirusassociatedvenousandarterialthromboticdisease
AT farrelljohn cytomegalovirusassociatedvenousandarterialthromboticdisease